Active ingredientEsketamine HydrochlorideCat. No. P-E093-001CAS 33643-47-9Family · Pharmaceutical analytical standards
Esketamine
The S-form of ketamine, one of its two mirror-image versions: introduced as an anaesthetic in Germany in 1997, in 2019 it was approved in the United States as a nasal spray, together with an oral antidepressant, for treatment-resistant depression. This family brings together the active ingredient, pharmacopoeial impurities and other impurities.
Did you know?It binds NMDA glutamate receptors more strongly than ordinary ketamine, which is an equal mixture of the two mirror-image forms.
Go to the active ingredient →Active ingredientEsketamine HydrochlorideCat. No. P-E093-001CAS 33643-47-9
Pharmacopoeial impurityEsketamine EP Impurity DCat. No. P-E093-002CAS 6740-88-1
Pharmacopoeial impurityEsketamine Hydrochloride EP Impurity DCat. No. P-E093-003CAS 33643-49-1
Pharmacopoeial impurityEsketamine Hydrochloride EP Impurity D HydrochlorideCat. No. P-E093-004CAS 33795-24-3
Active ingredientEsketamineCat. No. P-E093-005CAS 33643-46-8
ImpurityDeschloroketamineCat. No. P-E093-006CAS 7063-30-1No product matches your search.
EDQM standards 1
The official European Pharmacopoeia standards for this family.
ImpurityEsketamine impurity D CRSEDQM code Y0000338Family EsketamineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.